The effect of timing of stereotactic radiosurgery treatment of melanoma brain metastases treated with ipilimumab

Journal of Neurosurgery

Volumn 127, Issue 5, 2017, Pages 1007-1014

  Cohen Inbar, Or ^a,b   Shih, Han Hsun ^a,c,d   Xu, Zhiyuan ^a   Schlesinger, David ^a   Sheehan, Jason P ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b Rambam Health Care Center   (Israel)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Brain metastases; Ipilimumab; Melanoma; Oncology; Stereotactic radiosurgery

Indexed keywords

IPILIMUMAB; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN METASTASIS; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; COHORT ANALYSIS; EDEMA; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPOPHYSITIS; MALE; METASTATIC MELANOMA; NAUSEA AND VOMITING; NECROSIS; NEUROLOGICAL COMPLICATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEIZURE; STEREOTACTIC RADIOSURGERY; TIME TO TREATMENT; TREATMENT RESPONSE; BRAIN TUMOR; MELANOMA; MIDDLE AGED; RADIOSURGERY; SECONDARY; TIME FACTOR; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; BRAIN NEOPLASMS; FEMALE; HUMANS; IPILIMUMAB; MALE; MELANOMA; MIDDLE AGED; RADIOSURGERY; RETROSPECTIVE STUDIES; TIME FACTORS; YOUNG ADULT;

EID: 85028395613     PISSN: 00223085     EISSN: 19330693     Source Type: Journal    
DOI: 10.3171/2016.9.JNS161585     Document Type: Article

References (44)

1. Ahmed KA, Stallworth DG, Kim Y, Johnstone PA, Harrison LB, Caudell JJ, et al: Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. Ann Oncol 27:434-441, 2016
2. Ahmed KA, Stauder MC, Miller RC, Bauer HJ, Rose PS, Olivier KR, et al: Stereotactic body radiation therapy in spinal metastases. Int J Radiat Oncol Biol Phys 82:e803-e809, 2012
3. Arvold ND, Catalano PJ: Local therapies for brain metastases, competing risks, and overall survival. Int J Radiat Oncol Biol Phys 91:718-720, 2015
4. Bafaloukos D, Gogas H: The treatment of brain metastases in melanoma patients. Cancer Treat Rev 30:515-520, 2004
5. Bedrosian I, Faries MB, Guerry D IV, Elenitsas R, Schuchter L, Mick R, et al: Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. Ann Surg Oncol 7:262-267, 2000
6. Caruso JP, Cohen-Inbar O, Bilsky MH, Gerszten PC, Sheehan JP: Stereotactic radiosurgery and immunotherapy for metastatic spinal melanoma. Neurosurg Focus 38(3):E6, 2015
7. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, et al: Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial. Lancet Oncol 10:1037-1044, 2009
8. Cohen-Inbar O, Melmer P, Lee CC, Xu Z, Schlesinger D, Sheehan JP: Leukoencephalopathy in long term brain metastases survivors treated with radiosurgery. J Neurooncol 126:289-298, 2016
9. Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM: Systematic review of medical treatment in melanoma: Current status and future prospects. Oncologist 16:5-24, 2011
10. Gokaslan ZL, Aladag MA, Ellerhorst JA: Melanoma metastatic to the spine: A review of 133 cases. Melanoma Res 10:78-80, 2000
11. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
12. Kiess AP, Wolchok JD, Barker CA, Postow MA, Tabar V, Huse JT, et al: Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: Safety profile and efficacy of combined treatment. Int J Radiat Oncol Biol Phys 92:368-375, 2015
13. Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL: Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 117:227-233, 2012
14. Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, et al: Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study. J Clin Oncol 29:134-141, 2011
15. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al: Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373:23-34, 2015
16. Li HH, Wang YW, Chen R, Zhou B, Ashwell JD, Fornace AJ Jr: Ionizing radiation impairs T cell activation by affecting metabolic reprogramming. Int J Biol Sci 11:726-736, 2015
17. Lippitz B, Lindquist C, Paddick I, Peterson D, O'Neill K, Beaney R: Stereotactic radiosurgery in the treatment of brain metastases: The current evidence. Cancer Treat Rev 40:48-59, 2014
18. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al: Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial. Lancet Oncol 13:459-465, 2012
19. Mathew M, Tam M, Ott PA, Pavlick AC, Rush SC, Donahue BR, et al: Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. Melanoma Res 23:191-195, 2013
20. McWilliams RR, Rao RD, Buckner JC, Link MJ, Markovic S, Brown PD: Melanoma-induced brain metastases. Expert Rev Anticancer Ther 8:743-755, 2008
21. O'Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A, et al: Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov 3:1378-1393, 2013
22. O'Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, et al: Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-arm phase II study. Ann Oncol 21:1712-1717, 2010
23. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252-264, 2012
24. Patel KR, Lawson DH, Kudchadkar RR, Carthon BC, Oliver DE, Okwan-Duodu D, et al: Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases. Neuro Oncol 17:1312-1321, 2015
25. Patel KR, Shoukat S, Oliver DE, Chowdhary M, Rizzo M, Lawson DH, et al: Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases. Am J Clin Oncol [epub ahead of print], 2015
26. Phan GQ, Rosenberg SA: Adoptive cell transfer for patients with metastatic melanoma: The potential and promise of cancer immunotherapy. Cancer Contr 20:289-297, 2013
27. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, et al: CTLA-4 blockade with ipilimumab: Longterm follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 18:2039-2047, 2012
28. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al: Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526, 2011
29. Sahgal A, Aoyama H, Kocher M, Neupane B, Collette S, Tago M, et al: Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: Individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 91:710-717, 2015
30. Salvetti DJ, Nagaraja TG, McNeill IT, Xu Z, Sheehan J: Gamma Knife surgery for the treatment of 5 to 15 metastases to the brain: Clinical article. J Neurosurg 118:1250-1257, 2013
31. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF: Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 88:11-20, 1998
32. Schoenfeld JD, Mahadevan A, Floyd SR, Dyer MA, Catalano PJ, Alexander BM, et al: Ipilmumab and cranial radiation in metastatic melanoma patients: A case series and review. J Immunother Cancer 3:50, 2015
33. Shah DJ, Dronca RS: Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma. Mayo Clin Proc 89:504-519, 2014
34. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62:220-241, 2012
35. Silk AW, Bassetti MF, West BT, Tsien CI, Lao CD: Ipilimumab and radiation therapy for melanoma brain metastases. Cancer Med 2:899-906, 2013
36. Snell JW, Sheehan J, Stroila M, Steiner L: Assessment of imaging studies used with radiosurgery: A volumetric algorithm and an estimation of its error. Technical note. J Neurosurg 104:157-162, 2006
37. Song CW, Kim MS, Cho LC, Dusenbery K, Sperduto PW: Radiobiological basis of SBRT and SRS. Int J Clin Oncol 19:570-578, 2014
38. Stamell EF, Wolchok JD, Gnjatic S, Lee NY, Brownell I: The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys 85:293-295, 2013
39. Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler T, Bamberg M, et al: Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 102:1213-1218, 2010
40. Tazi K, Hathaway A, Chiuzan C, Shirai K: Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery. Cancer Med 4:1-6, 2015
41. Walker PR, Calzascia T, Dietrich PY: All in the head: Obstacles for immune rejection of brain tumours. Immunology 107:28-38, 2002
42. Weber JS, Amin A, Minor D, Siegel J, Berman D, O'Day SJ: Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: Retrospective analysis of data from a phase 2 trial. Melanoma Res 21:530-534, 2011
43. Wouters J, Stas M, Gremeaux L, Govaere O, Van den Broeck A, Maes H, et al: The human melanoma side population displays molecular and functional characteristics of enriched chemoresistance and tumorigenesis. PLoS One 8:e76550, 2013
44. Xu Z, Lee CC, Ramesh A, Mueller AC, Schlesinger D, Cohen-Inbar O, et al: BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases. J Neurosurg [epub ahead of print May 20, 2016. DOI: 10.3171/2016.2.JNS1633]